![Cosimo Saponaro](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Cosimo Saponaro active positions
Companies | Position | Start | End |
---|---|---|---|
GELESIS INC | Corporate Officer/Principal | - | - |
Chief Operating Officer | - | - | |
Gelesis Srl
![]() Gelesis Srl BiotechnologyHealth Technology Gelesis Srl engages in the manufacture, research, and development of treatment solutions and interventions for gastrointestinal diseases. It also develops products and technologies which offers solutions to induce weight loss, improve glycemic control, and manage blood sugar levels in overweight and obese patients, including those with prediabetes and type 2 diabetes. The company was founded in 2009 and is headquartered in Calimera, Italy. | Director/Board Member | - | - |
Career history of Cosimo Saponaro
Statistics
International
United States | 2 |
Italy | 2 |
Operational
Chief Operating Officer | 1 |
Corporate Officer/Principal | 1 |
Director/Board Member | 1 |
Sectoral
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Gelesis, Inc.
![]() Gelesis, Inc. BiotechnologyHealth Technology Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA. | Health Technology |
Gelesis Srl
![]() Gelesis Srl BiotechnologyHealth Technology Gelesis Srl engages in the manufacture, research, and development of treatment solutions and interventions for gastrointestinal diseases. It also develops products and technologies which offers solutions to induce weight loss, improve glycemic control, and manage blood sugar levels in overweight and obese patients, including those with prediabetes and type 2 diabetes. The company was founded in 2009 and is headquartered in Calimera, Italy. | Health Technology |
- Stock Market
- Insiders
- Cosimo Saponaro
- Experience